Topic: combination therapy
Concerto HealthAI has inked its second real-world data collaboration with a Big Pharma company in as many weeks.
Bristol-Myers is testing its leukemia therapy Sprycel in a phase 2 combo study with the anti-PD-1 drug Opdivo in non-small cell lung cancer patients.
Researchers at Duke University say they’ve figured out why a class of cancer drugs called MMP inhibitors failed to stop cancer from spreading.
Idera touts higher response rate from the combo than Yervoy alone and a 76.5% disease control rate.
Scientists have early evidence that Amgen's oncolytic virus plus PD-1 and MEK inhibitors could be effective in treating melanoma.
A combination of Novartis' Farydak and Incuron's experimental CBL0137 made neuroblastoma disappear In mice.
Nektar Therapeutics poached Genentech immunotherapy leader Wei Lin to head up its oncology program and serve as VP of clinical development.
A phosphor-binding site on aberrantly spliced BRAF V600E could become a new target against drug-resistant melanoma.
Scientists at Vanderbilt University found that a glutaminase inhibitor improved the anticancer activity of CAR-T cells.
A bottleneck of immunotherapy combination trials has put the field’s advancement on hiatus as researchers and drugmakers wait for the next discovery.